Dementia

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
older patient and younger individual holding hands
FDA Alert
FDA Approves Auvelity for Agitation in Alzheimer Disease Dementia
05/01/2026
Anthony Calabro, MA
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
05/01/2026
fda alert
FDA Alert
fda alert
FDA Converts Alzheimer Disease Treatment to Traditional Approval
07/28/2023
Leigh Precopio
The FDA has examined the results of a recent confirmatory trial to verify the clinical benefit of an amyloid beta-directed antibody for the treatment of Alzheimer disease.
07/28/2023
FDA Alert
fda
FDA Alert
FDA Approves First Treatment of Agitation in Patients With Alzheimer Dementia
05/15/2023
Jessica Ganga
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
05/15/2023
FDA Roundup
FDA Roundup
Key FDA Approvals Include First OTC, Nonprescription Daily Oral Contraceptive, First Monoclonal Injection to Prevent RSV in Infants, and More
07/28/2015
Anthony Calabro, MA
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in June and July, including the first over-the-counter, nonprescription daily oral contraceptive, the first monoclonal...
07/28/2015